Immune system effects of echinacea, ginseng, and astragalus: A review

Integrative Cancer Therapies

Volumn 2, Issue 3, 2003, Pages 247-267

  Block, Keith I ^a,b,c   Mead, Mark N ^a  

^a Block Center Integrative Cancer Care   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Astragalus; Cancer; Echinacea; Ginseng; Immune system; Upper respiratory infections

Indexed keywords

ANTIFATIGUE AGENT; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; ASCORBIC ACID; ASPARAGINE; ASTRAGALUS EXTRACT; BETAINE; CAFFEIC ACID; CICHORIC ACID; CYTOKINE; ECHINACEA EXTRACT; ECHINACEA PURPUREA EXTRACT; ESBERITOX; ESSENTIAL OIL; FORMONONETIN; GINSENG EXTRACT; GINSENOSIDE; GLUCURONIC ACID; GLYCOPROTEIN; HERBACEOUS AGENT; IMMUNOGLOBULIN G; IMMUNOSTIMULATING AGENT; INFLUENZA VACCINE; ISOFLAVAN DERIVATIVE; PHYTOSTEROL; PLANT EXTRACT; POLYSACCHARIDE; SAPONIN DERIVATIVE; SITOSTEROL; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ALTERNATIVE MEDICINE; ANTIBODY PRODUCTION; ASTRAGALUS PLANT; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CELLULAR IMMUNITY; CLINICAL TRIAL; COMMON COLD; COMPLEMENT ACTIVATION; DISEASE RESISTANCE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG QUALITY; DRUG SAFETY; DRUG SYNTHESIS; DRUG USE; ECHINACEA ANGUSTIFOLIA; ECHINACEA PALLIDA; ECHINACEA PURPUREA; EDEMA; GINSENG; GRANULOCYTE; HERB; HERBAL MEDICINE; HOMEOPATHY; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOREACTIVITY; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFECTION RESISTANCE; LEUKOCYTE; LONG TERM CARE; MACROPHAGE ACTIVATION; MALIGNANT NEOPLASTIC DISEASE; MENTAL STRESS; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; NORTH AMERICA; OVERSTIMULATION; PHAGOCYTOSIS; PHYTOCHEMISTRY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SLEEP DISORDER; STIMULATION; SYMPTOM; TREATMENT INDICATION; UPPER RESPIRATORY TRACT INFECTION;

ASTRAGALUS; ECHINACEA;

EID: 0141565365     PISSN: 15347354     EISSN: None     Source Type: Journal    
DOI: 10.1177/1534735403256419     Document Type: Review

References (243)

1. Jonas WB. Alternative medicine. J Fam Pract. 1997;45(1):34-37.
2. Israelsen LD. Phytomedicines: the greening of modern medicine. J Altern Comp Med. 1995;1(3):245-248.
3. Jones FA. Herbs-useful plants. Their role in history and today. Eur J Gastroenterol Hepatol. 1996;8(12):1227-1231.
4. Prittenger J. Herbal treatments find their way into mainstream America. Wisconsin Med J. 1997;96(3):30-31.
5. Astin JA. Why patients use alternative medicine: results of a national study. JAMA 1998;279:1548-1553.
6. Johnston B. One-third of nation's adults use herbal remedies: market estimated at $3.24 billion. HerbalGram. 1997;40:552.
7. Brevoort P. The US botanical market: an overview. HerbalGram, 1996;36:49-57.
8. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998;280(18):1569-1575.
9. Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med. 1993;328(4):246-252.
10. Vuckovic N, Nichter M, Changing patterns of pharmaceutical practice in the United States. Soc Sci Med. 1997;44(9):1285-1302.
11. Shaw D, Leon C, Kolev S, Murray V. Traditional remedies and food supplements. A 5-year toxicological study (1991-1995). Drug Safe, 1997;17(5):342-356.
12. Brevoort P, The booming US botanical market: a new overview. HerbalGram. 1998;44:33-46.
13. Benzi G, Ceci A. Herbal medicines in European regulation. Pharmacol Res. 1997;35(5):355-362.
14. Harrison P. Herbal medicine takes root in Germany. CMAJ. 1998;158(5):637-639.
15. Mahady GB, Parrot J, Lee C, Yun GS, Dan A. Botanical dietary supplement use in peri- and postmenopausal women. Menopause. 2003;10(1):65-72.
16. Bernstein BJ, Grasso T. Prevalence of complementary and alternative medicine use in cancer patients. Oncology (Huntingt). 2001;15(10):1267-1272.
17. Wolf H. Can orally applied immunomodulators improve local defense? In: Masahi KN, ed. Immunotherapy of Infections. New York: Marcel Dekker; 1994:351-355.
18. Parnham MJ. Benefit-risk assessment of the squeezed sap of the purple coneflower (Echinacea purpurea) for long-term oral immunostimulation. Phytomedicine. 1996;3(1):95-102.
19. Schulz V, Hansel R, Tyler VE. Agents that increase resistance to diseases. In: Rational Phytotherapy. NewYork: Springer-Verlag; 1998:269-285.
20. Whiteside TL, Herberman RB. Role of human natural killer cells in health and disease. Clin Diag Lab Immunol. 1994;1(2):125-133.
21. Smith RT. Cancer and the immune system. Pediatric Clin North Amer. 1994;41(4):841-850.
22. Block KI, Boyd DB, Gonalez N, Vojdani A. Point counter-point: the immune system in cancer. Int Cancer Ther. 2002; 1 (3):294-316.
23. Hicks KL, Chemaly RF, Kontoyiannis DP. Common community respiratory viruses in patients with cancer: more than just "common colds." Cancer. 2003;97(10):2576-2588.
24. Buche J. Alternative Cancer Therapies; 2000. Available at: http://seasilver.threadnet.com/Preventorium/thesis.htm.
25. Kruzel T. Cancer of the Prostate-A Naturopathic Perspective; N.D. Available at: http://aanp.net/Library/articles.lay/ProstateCancerTK.html
26. Keeshan MD, Cancer: An Overview of Nutritional and Holistic Approaches to Its Treatment; 1997. Available at: http://www.notdoctors.com/cancview.html
27. Pan MJ. Cancer Treatment With Fu Zheng Pei Ben Principle. Fujian, China: Fujian Science and Technology Publishing House; 1987.
28. Pepping J. Echinacea Am J Health Syst Pharmacol. 1999; 56(2):121-122.
29. Tarleton A. Echinacea Juice for Immune Stimulation-Assessment of Risks and Benefits. Austin, Tex: American Botanical Council. HerbClip No. 100874; December 17, 1997.
30. Bauer R. Echinacea: biological effects and active principles. In: Lawson LD, Bauer R, eds. Phytomedicines of Europe: Chemistry and Biological Activity. Washington, DC: American Chemical Society; 1998:140-157.
31. Bauer R, Wagner H. Echinacea: Handbuch fur Arzte, Apotheker und andere Naturwissenschaftler: Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft; 1990.
32. Tyler VE. Phytomedicines in Western Europe: their potential impact on herbal medicine in the United States. HerbalGram. 1994;30:24-31.
33. Keller K. Legal requirements for the use of phytopharmaceutical drugs in the Federal Republic of Germany. J Ethnopharmacol. 1991;32:225-229.
34. Melchart D, Linde K, Worku F, Bauer R, Wagner H. Immunomodulation with Echinacea: a systematic review of controlled trials. Phytomedicine. 1994;1:245-254.
35. Dorsch W. Clinical application of extracts from Echinacea puvpurea or Echinacea pallida. Critical evaluation of controlled clinical studies. Z Arztl Fortbild Jena. 1996;90:117-122.
36. Roesler J, Steinmuller C, Kinderlen A, et al. Application of purified polysaccharides from cell cultures of the plant Echinacea purpurea to mice mediates protection against systemic infections with Listeria monocytogenes and Candida albicans. Int J Immunophamnac. 1991;1(1)3:27-38.
37. See DM, Broumand N, Sahl L, Tilles JG. In vitro effects of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients. Immunopharmacology. 1997;35:229-235.
38. Eichler F, Krueger GR. Effects of non-specific immuno-stimulants (Echinacin, isoprinosine and thymus factors) on the infection and antigen expression in herpesvirus-6 exposed human lymphoid cells. In Vivo. 1994;8:565-575.
39. Lersch C, Zeuner M, Bauer A, et al. Stimulation of the immune response in outpatients with hepatocellular carcinomas by low doses of cyclophosphamide (LDCY), Echinacea purpurea extracts (Echinacin) and thymostimulin. Arch Geschwulsforschung. 1990;60:379-383.
40. Lersch CM, Zeuner M, Bauer A, et al. Nonspecific immunostimulation with low doses of cyclophosphamide, thymostimulin, and Echinacea purpurea extracts (Echinacin) in patients with far advanced colorectal cancers: preliminary results. Cancer Invest. 1992;10:343-348.
41. Reuss D. The treatment of primary chronic polyarthritis with Echinacin. Rheumatology. 1996;5:29-32.
42. Viehmann P. Erfahrungen mit einer Echinacea-haltigen Hautsalbe. Erfahrungsheilk. 1978;27:353-358.
43. Gunning K, Steele P. Echinacea for the prevention of upper respiratory tract infections. J Fam Pract. 1999;48(2):93.
44. Bauer VR, Jurcic K, Puhlmann J, Wagner H. Immunologic in vivo and in vitro studies on Echinacea extracts. Arzneimittelforschung. 1988;38:276-281.
45. Wildfeuer A, Mayerhofer D. The effects of plant preparations on cellular functions in body defense. Arzneimittelforschung. 1994;44:361-366.
46. Couch JF, Giltner LT. An experimental study of Echinacea therapy. J Agric Res. 1920;20:63-84.
47. Osowski S, Rostock M, Bartsch HH, Massing U. Pharmaceutical comparability of different therapeutic Echinacea preparations. Forsch Komplementarmed Klass Naurheilkd. 2000;7(6):294-300.
48. Rininger JA, Kickner S, Chigurupati P, McLean A, Franck Z. Immuno-pharmacological activity of Echinacea preparations following simulated digestion on murine macrophages and human peripheral blood mononuclear cells. J Leukoc Biol. 2000;68(4):503-510.
49. Coeugniet EG, Elek E. Immunomodulation with Viscum album and Echinacea purpurea extracts. Onkologie. 1987;10(suppl 3):27-33.
50. Bauer R. Echinacea drugs-effects and active ingredients. Zeitschrift fur Arztliche Fortbildung (Jena). 1996;90(2):111-115.
51. Luettig B, Steinmuller C, Gifford GE, Wagner H, Lohmann-Matthes ML. Macrophage activation by the polysaccharide arabinogalactan isolated from plant cell cultures of Echinacea purpurea. JNCI. 1989;81(9):669-675.
52. Stimpel M, Proksch A, Wagner H, Lohmann-Matthes ML. Macrophage activation and induction of macrophage cytotoxicity by purified polysaccharide fractions from the plant Echinacea purpurea. Infect Immun. 1984;46(3):845-849.
53. Burger RA, Torres AR, Warren RP, Caldwell VD, Hughes BG. Echinacea-induced cytokine production by human macrophages. Int J Immunopharmacol. 1997;19(7):371-379.
54. Elsasser-Beile U, Willenbacher W, Bartsch HH, Gallati H, Schulte Monting J, von Kleist S. Cytokine production in leukocyte cultures during therapy with Echinacea extract. J Clin Lab Anal. 1996;10(6):441-445.
55. Tubaro A, Tragni E, Del Negro P, Galli CL, Della Loggia R. Anti-inflammatory activity of a polysaccharidic fraction of Echinacea angustifolia. J Pharmacy Pharmacol. 1987;39(7):567-569.
56. Tragni E, Galli CL, Tubaro A, Del Negro P, Della Loggia R. Anti-inflammatory activity of Echinacea angustifolia fractions separated on the basis of molecular weight. Pharmacol Res Commun. 1988;20(suppl 5):87-90.
57. Currier NL, Miller SC. Echinacea purpurea and melatonin augment natural-killer cells in leukemic mice and prolong life span. J Altern Comp Med. 2001;7(3):241-251.
58. Alban S, Classen B, Brunner G, Blaschek W. Differentiation between the complement modulating effects of an arabinogalactan-protein from Echinacea purpurea and heparin. Planta Med. 2002;68(12):1118-1124.
59. Rehman J, Dillow JM, Carter SM, Chou J, Le B, Maisel AS. Increased production of antigen-specific immunoglobulins G and M following in vivo treatment with the medicinal plants Echinacea angustifolia and Hydrastis canadensis. Immunol Lett. 1999;68(2-3):391-395.
60. South EH, Exon JH. Multiple immune function in rats fed echinacea extracts. Immunopharm Immunotoxicol. 2001;23(3): 411-421.
61. Binns SE, Hudson J, Merali S, Arnason JT. Antiviral activity of characterized extracts from Echinacea spp. (Heliantheae: Asteraceae) against herpes simplex virus (HSV-I). Planta Med. 2002;68(9):780-783.
62. Raso GM, Pacilio M, Di Carlo G, Esposito E, Pinto L, Meli R. In-vivo and in-vitro anti-inflammatory effect of Echinacea purpurea and Hypericum perforatum. J Pharm Pharmacol. 2002;54(10): 1379-1383.
63. Clifford LJ, Nair MG, Rana J, Dewitt DL. Bioactivity of alkamides isolated from Echinacea purpurea (L.) Moench. Phytomedicine. 2002;9(3):249-253.
64. Melchart D, Linde K,Worku F, et al. Results of five randomized studies on the immunomodulatory activity of preparations of Echinacea. J Altern Comp Med. 1995;1(2):145-160.
65. Fugh-Berman A. Homeopathy. In: Alternative Medicine: What Works. Tucson, Ariz: Odonian Press; 1996:126-138.
66. Reilly DT, Taylor MA, McSharry C, Aitchison T. Is homoeopathy a placebo response? Controlled trial of homoeopathic potency, with pollen in hayfever as model. Lancet. 1986;2(8512):881-886.
67. Linde K, Clausius N, Ramirez G, et al. Are the clinical effects of homeopathy placebo effects? A meta-analysis of placebo-controlled trials. Lancet. 1997;350(9081):834-843.
68. Alibeu JP, Jobert J. Aconite in homeopathic relief of post-operative pain and agitation in children. Pediatrie. 1990;45(7-8):465-466.
69. Jacobs J, Jimenez LM, Gloyd SS, Gale JL, Crothers D. Treatment of acute childhood diarrhea with homeopathic medicine: a randomized clinical trial in Nicaragua. Pediatrics. 1994;93(5):719-725.
70. Kim LS, Waters RF, Burkholder PM. Immunological activity of larch arabinogalactan and Echinacea: a preliminary, randomized, double-blind, placebo-controlled trial. Altern Med Rev. 2002;7(2):138-149.
71. Schwarz E, Metzler J, Diedrich JP, Freudenstein J, Bode C, Bode JC. Oral administration of freshly expressed juice of Echinacea purpurea herbs fail to stimulate the nonspecific immune response in healthy young men: results of a double-blind, placebo-controlled crossover study. J Immunother. 2002;25(5):413-420.
72. Lersch C, Gain T, Lorenz R, Classen M. Chemoimmuno-therapy of malignancies of the gastrointestinal tract. Immunitat und Infektion. 1994;22(2):58-59.
73. Vonau B, Chard S, Mandalia S, Wilkinson D, Barton SE. Does the extract of the plant Echinacea purpurea influence the clinical course of recurrent genital herpes? Int J STD AIDS. 2001;12(3):154-158.
74. Melchart D, Clemm C, Weber B, et al. Polysaccharides isolated from Echinacea purpurea herba cell cultures to counteract undesired effects of chemotherapy-a pilot study. Phytother Res. 2002;16(2):138-142.
75. Bauer R. Echinacea: biological effects and active principles. In: Lawson LD, Bauer R, eds. Phytomedicines of Europe: Chemistry and Biological Activity. Washington, DC: American Chemical Society; 1998:140-157.
76. Braunig B, Knick E. Therapeutische Erfahrungen mit Echinacea pallidae bei grippalen Infekten. Naturheilpraxis. 1993;1:72-75.
77. Braunig B, Dorn M, Knick E. Echinacea purpurea radix: Zur Starkung der korpereigenen Abwehr bei grippalen Infekten. Zeitsch Phytotherapie. 1992;13:7-13.
78. Scaglione F, Lund B. Efficacy in the treatment of the common cold of a preparation containing echinacea extract. Int J Immunother. 1995;11:163-166.
79. Schoneberger D. Influence of the immunostimulating effects of the pressed juice on the duration of density of the common cold. Results of a double-blind clinical trial. Forum Immunologie. 1992;2:18-22.
80. Hoheisel O, Sandberg M, Bertram S, Bulitta M, Schafer M. Echinagard treatment shortens the course of the common cold: a double-blind placebo-controlled clinical trial. Eur J Clin Res. 1997;9:261-268.
81. Brinkeborn RM, Shah DV, Degenring FH. Echinaforce and other echinacea fresh plant preparations in the treatment of the common cold. A randomized, placebo controlled, double-blind clinical trial. Phytomedicine. 1999;6(1):1-6.
82. Vorberg G, Schneider B. Pflanzliches Immunstimulans verkurzt grippalen Infeckt. Doppelblindstudie belegt die Steigerung der unspezifischen Infektabwehr. Arztliche Forsch. 1989;36:3-8.
83. Dorn M. Milerung grippaler Effeckt dutch ein pflanzliches Immunstimulans. Nutur Ganzheitsmedizin. 1989;2:314-319.
84. Lindenmuth GF, Lindenmuth EB. The efficacy of echinacea compound herbal tea preparation on the severity and duration of upper respiratory and flu symptoms: a randomized, double-blind placebo-controlled study. J Altern Comp Med. 2000;6(4):327-334.
85. Henneicke-vonZepelin H, Hjentschel C, Schnitker J, Kohnen R, Kohler G, Wustenberg P. Efficacy and safety of a fixed combination phytomedicine in the treatment of the common cold (acute viral respiratory track infection): results of a randomized, double blind, placebo controlled, multicentre trial. Curr Med Res Opin. 1999;15(3)214-227.
86. Schulten B, Bulitta M, Ballering-Bruhl B, Koster U, Schafer M. Efficacy of Echinacea purpurea in patients with a common cold. A placebo-controlled, randomized, double-blind clinical trial. Arzneimittelforschung. 2001;51(7):563-568.
87. Vorberg G. Bei Erkaltung unspezifische Immunabwehr stimulieran: Doppelblindstudie zeigt: Das bewahrte Phytotherapeutikum. Esberitox verkurzt die Symptommatik. Arztliche Praxis. 1984;36:97-98.
88. Reitz HD. Immunmodulatoren mit pflanzlichen Wirkstoffen: eine wissenschafliche Studie am Beispiel Esberitox N. Notabene Med. 1990;20:362-366.
89. Galea S, Thacker K. Double-blind prospective trial investigating the effectiveness of a commonly prescribed herbal remedy in altering the duration, severity and symptoms of the common cold. Unpublished manuscript, 1996.
90. Barrett BP, Brown RL, Locken K, Maberry R, Bobula JA, D'Alessio D. Treatment of the common cold with unrefined echinacea. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137(12):939-946.
91. Forth H, Beuscher N. Beeinflussing der Hafigkeit banaler Erkaltungsinfekte furch Esberitox. Zeitsch Allgemeinmedizin. 1981;57:2272-2275.
92. Schmidt U, Albrech TM, Schenk N. Pflankliches Immunstimulans senket Haufigkeit grippaler Infekte: Plazebokontrollierte Doppel blindstudie mit einem kombineierten Echinacea-Praparat mit 646 Studenten der Kolner Universitat. Natur Ganzheitsmedizin. 1990;3:277-281.
93. Grimm W, Muller HH. A randomized controlled trial of the effect of fluid extract of Echinacea purpurea on the incidence and severity of colds and respiratory infections. Am J Med. 1999;106(2):138-143.
94. Melchart D, Walther E, Linde K, Brandmaier R, Lersch C. Echinacea root extracts for the prevention of upper respiratory tract infections: a double-blind, placebo-controlled randomized trial. Arch Fam Med. 1998;7(6):541-545.
95. Schoneberger D. Einflub der immunstimulierenden Wirkung von Prebsaft aus Herba echinacea purpurea auf Verlauf und Schweregrad von Erkaltungskrankheiten. Ergebnisse einer Doppelblindstudie. Forum Immunologie. 1992;2:18-22.
96. Turner RB, Riker DK, Gamgemi JD. Ineffectiveness of echinacea for prevention of experimental rhinovirus colds. Antimicrob Agents Chemother. 2000;44(6)1708-1709.
97. Giles JT, Palat CT 3rd, Chien SH, Chang ZG, Kennedy DT. Evaluation of echinacea for treatment of the common cold. Pharmacotherapy. 2000;20(6):690-697.
98. Ness AR, Khaw KT, Bingham S, Day NE. Vitamin C status and respiratory function. Eur J Clin Nutr. 1996;50(9):573-579.
99. De la Fuente M, Ferrandez MD, Burgos MS, Soler A, Prieto A, Miquel J. Immune function in aged women is improved by ingestion of vitamins C and E. Can J Physiol Pharmacol. 1998;76(4):373-380.
100. Schmidt K. Interaction of antioxidative micronutrients with host defense mechanisms. A critical review. Int J Vitamin Nutr Res. 1997;67(5):307-311.
101. Hughes DA. Effects of dietary antioxidants on the immune function of middle-aged adults. Proc Nutr Soc. 1999;58(1):79-84.
102. Penn ND, Purkins L, Kelleher J, Heatley RV, Mascie-Taylor BH, Belfield PW. The effect of dietary supplementation with vitamins A, C and E on cell-mediated immune function in elderly long-stay patients: a randomized controlled trial. Age Ageing. 1991;20(3):169-174.
103. Delafuente JC, Prendergast JM, Modigh A. Immunologic modulation by vitamin C in the elderly. Int J Immunopharmacol. 1986;8(2):205-211.
104. Steele RW, Charlton RK. Immune modulators as antiviral agents. Clin Lab Med. 1987;7(4):911-924.
105. \Hemila H. Vitamin C and common cold incidence: a review of studies with subjects under heavy physical stress. Int J Sports Med. 1996;17(5):379-383.
106. Peters-Futre EM. Vitamin C, neutrophil function, and upper respiratory tract infection risk in distance runners: the missing link. Exercise Immunol Rev. 1997;3:32-52.
107. Grimble RF. Effect of antioxidative vitamins on immune function with clinical applications. Int J Vitamin Nutr Res. 1997;67(5):312-320.
108. Kelley DS, Bendich A. Essential nutrients and immunologic functions. Am J Clin Nutr. 1996;63(6):994S-996S.
109. Scrimshaw NS, San Giovanni JP. Synergism of nutrition, infection, and immunity: an overview. Am J Clin Nutr. 1997;66(2):464S-477S.
110. Anonymous. Nutrition, Immunity, and Infection. Proceedings of a symposium. Madrid, Spain, October 24-25, 1994. Am J Clin Nutr. 1997;66(2):459S-529S.
111. Barrett B, Locken K, Maberry R, et al. The Wisconsin Upper Respiratory Symptom Survey (WURSS): a new research instrument for assessing the common cold. J Fam Pract. 2002;51(3):265.
112. Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine. 2003;10(1):66-86.
113. Barrett B. Echinacea: a safety review. HerbalGram. 2003;57:36-39.
114. Mullins RJ, Heddle R. Adverse reactions associated with echinacea: the Australian experience. Ann Allergy Asthma Immunol. 2002;88(1):42-51.
115. Li W, Sun Y, Fitzloff JF, van Breemen RB. Evaluation of commercial ginkgo and Echinacea dietary supplements for colchicines using liquid chromatography-tandem mass spectrometry. Chem Res Toxicol. 2002;15(9):1174-1178.
116. Gilroy CM, Steiner JF, Byers T, Shapiro H, Georgian W. Echinacea and truth in labeling. Acrh Intern Med. 2003;163(6): 699-704.
117. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs. 2001;61(15): 2163-2175.
118. Liu CX, Xiao PG. Recent advances on ginseng research in China. J Ethnopharmacol. 1992;36(1):27-38.
119. Wilkie A, Cordess C. Ginseng-a root just like a carrot? JR Soc Med. 1994;87(10):594-595.
120. Kumar R, Grover SK, Divekar HM, Gupta AK, Shyam R, Srivastava KK. Enhanced thermogenesis in rats by Panax ginseng, multivitamins and minerals. Int J Biometeorol. 1996;39(4):187-191.
121. Cui J, Garle M, Eneroth P, Bjorkhem I. What do commercial ginseng preparations contain? Lancet. 1994;344(8915):134.
122. Anonymous. Herbal roulette. Consumer Reports. 1995; 60(11):698-705.
123. Walker AF. What is in ginseng? Lancet. 1994;344(8922):619.
124. Hall T, Lu, ZZ, Yat PN, et al. Evaluation of consistency of standardized Asian ginseng products in the Ginseng Evaluation Program. HerbalGram. 2001;52:31-45.
125. Tang W, Eisenbrand G. Chinese Drugs of Plant Origin. Berlin, Heidelberg: Springer-Verlag; 1992:711-737.
126. Sticher O. Biochemical, pharmaceutical and medical perspectives on ginseng. In: Lawson LD, Bauer R, eds. Phytomedicines of Europe: Chemistry and Biological Activity. Oxford University Press: American Chemical Society; 1998:221-240.
127. Zhang D, Yasuda T, Yu Y, et al. Ginseng extract scavenges hydroxyl radical and protects unsaturated fatty acids from decomposition caused by iron-mediated lipid peroxidation. Free Radic Biol Med. 1996;20(1):145-150.
128. Hansson M, Asea A, Ersson U, Hermodsson S, Hellstrand K. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J Immunol. 1996;156(1):42-47.
129. Brune M, Hansson M, Mellqvist UH, Hermodsson S, Hellstrand K. NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur J Haematol. 1996;57(4):312-319.
130. Kono K, Salazar-Onfray F, Petersson M, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol. 1996;26(6):1308-1313.
131. Beisel WR. Nutrition and immune function: overview. J Nutr. 1996;126:2611S-2615S.
132. Moriguchi S, Kobayashi N, Kishino Y. High dietary intakes of vitamin E and cellular immune functions in rats. J Nutr. 1990;120(9):1096-1102.
133. Anderson R, van Antwerpen VL. Vitamins in the maintenance of optimum immune functions and in the prevention of phagocyte-mediated tissue damage and carcinogenesis. Bibliotheca Nutr Diet. 1995;52:66-74.
134. Krinsky N. Effects of carotenoids in cellular and animal systems. Am J Clin Nutr. 1991;53:2385-2465.
135. Lee YS, Chung IS, Lee IR, Kim KH, Hong WS, Yun YS. Activation of multiple effector pathways of immune system by the antineoplastic immunostimulator acidic polysaccharide ginsan isolated from Panax ginseng. Anticancer Res. 1997; 17(1A):323-331.
136. Akagawa G, Abe S, Tansho S, Uchida K, Yamaguchi H. Protection of C3H/HEJ mice from development of Candida albicans infection by oral administration of Juzen-taiho-to and its component, Ginseng radix: possible roles of macrophages in the host defense mechanisms. Immunopharmacol Immunotoxicol. 1996;18(1):73-89.
137. Luo YM, Cheng XJ, Yuan WX. Effects of ginseng root saponins and ginsenoside Rbl on immunity in cold water swim stress mice and rats. Acta Pharmacol Sin. 1993;14(5):401-404.
138. Kim JY, Germolec DR, Luster MI. Panax ginseng as a potential immunomodulator: studies in mice. Immunopharmacol Immunotoxicol. 1990;12(2):257-276.
139. Jie YH, Cammisuli S, Baggiolini M. Immunomodulatory effects of Panax ginseng C.A. Meyer in the mouse. Agents Actions. 1984;15(3-4):386-391.
140. Yeung HW, Cheung K, Leung KN. Immunopharmacology of Chinese medicine 1, ginseng induced immunosuppression in virus-infected mice. Am J Chin Med. 1982;10(1-4):44-54.
141. Chong SK, Brown HA, Rimmer E, Oberholzer V, Hindocha P, Walker-Smith JA. In vitro effect of Panax ginseng on phytohaemagglutinin-induced lymphocyte transformation. Int Arch Allergy Appl Immunol. 1984;73(3):216-220.
142. Wang H, Actor JK, Indrigo J, Olsen M, Dasgupta A. Asian and Siberian ginseng as a potential modulator of immune function: an in vitro cytokine study using mouse macrophages. Clin Chim Acta. 2003;327(1-2):123-128.
143. Gupta S, Agarwal SS, Epstein LB, Fernandez G, Good RA. Panaxginseng: a new mitogen and interferon inducer. Clin Res. 1980;504A:28-32.
144. Ha TU, Lee JH, Kim SH. Effect of Panax ginseng on the graft-versus-host reaction, production of leukocyte migration inhibitory factor and expulsion of adult Trichindla spiralis in mice. J Kor Soc Microbiol. 1986;21:132-144.
145. Song ZJ, Johansen HK, Faber V, Hoiby N. Ginseng treatment enhances bacterial clearance and decreases lung pathology in athymic rats with chronic P. aeruginosa pneumonia. APMIS. 1997;105(6):438444.
146. Song Z, Kharazmi A, Wu H, et al. Effects of ginseng treatment on neutrophil chemiluminescence and immunoglobulin G subclasses in a rat model of chronic Pseudomonas aeruginosa pneumonia. Clin Diag Lab Immunol. 1998;5(6):882-887.
147. Song Z, Wu H, Mathee K, Hoiby N, Kharazmi A. Gerimax ginseng regulates both humoral and cellular immunity during chronic Pseudomonas aeruginosa lung infection. J Altern Comp Med. 2002;8(4)459-466.
148. Hu S, Concha C, Lin F, Persson Waller K. Adjuvant effect of ginseng extracts on the immune responses to immunization against Staphylococcus aureus in dairy cattle. Vet Immunol Immunopathol. 2003;91(1):29-37.
149. Rivera E, Daggfeldt A, Hu S. Ginseng extract in aluminum hydroxide adjuvanted vaccines improves the antibody response of pigs to porcine parvovirus and Erysipelothrix rhusiopathiae. Vet Immunol Immunopathol. 2003;91(1):19-27.
150. Rivera E, Hu S, Concha C. Ginseng and aluminum hydroxide act synergistically as vaccine adjuvants. Vaccine. 2003;21(11-12):1149-1157.
151. Hu S, Concha C,Johannisson A, Meglia G, Waller KP. Effect of subcutaneous injection of ginseng on cows with subclinical Staphylococcus aureus mastitis. J Vet Med B Infect Dis Vet Public Health. 2001;48(7):519-528.
152. Yun YS, Moon HS, Oh YR, Jo SK, Kim YJ, Yun TK. Effect of red ginseng on natural killer cell activity in mice with lung adenoma induced by urethan and benzo(a)pyrene. Cancer Detect Prev. 1987;1(suppl):301-309.
153. Jie YH, Cammisuli S, Baggiolini M. Immunomodulatory effects of Panax ginseng C.A. Meyer in the mouse. Agents Actions. 1984;15(3-4):386-391.
154. Mizuno M, Yamada J, Terai H, Kozukue N, Lee YS, Tsuchida H. Differences in immunomodulating effects between wild and cultured Panax ginseng. Biochem Biophys Res Comm. 1994;200(3):1672-1678.
155. Liu M, Zhang JT. Studies on the mechanisms of immunoregulatory effects of ginsenoside Rgl in aged rats. Acta Pharmacol Sin. 1996;31(2):95-100.
156. Liu M, Zhang JT. Immunoregulatory effects of ginsenoside Rgl in aged rats. Acta Pharmacol Sin. 1995;30(11):818-823.
157. Niu YP, Jin JM, Gao RL, Xie GL, Chen XH. Effects of ginsenosides Rgl and Rbl on proliferation of human marrow granulocyte-macrophage progenitor cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2001;9(2):178-180.
158. Vogler BK, Pittler MH, Ernst E. The efficacy of ginseng. A systematic review of randomised clinical trials. Eur J Clin Pharmacol. 1999;55:567-575.
159. Bahrke MS, Morgan WP. Evaluation of the ergogenic properties of ginseng. Sports Med. 2000;29:113-133.
160. Liu J, Wang S, Liu H, Yang L, Nan G. Stimulatory effect of saponin from Panax ginseng on immune function of lymphocytes in the elderly. Mech Ageing Dev. 1995;83(1):43-53.
161. Wu D, Meydani M, Leka LS, et al. Effect of dietary supplementation with black currant seed oil on the immune response of healthy elderly subjects. Am J Clin Nutr. 1999; 70(4):536-543.
162. Eze MO. Membrane fluidity, reactive oxygen species, and cell-mediated immunity: implications in nutrition and disease. Med Hypotheses. 1992;37(4):220-224.
163. Scaglione F, Ferrara F, Dugnani S, Falchi M, Santoro G, Fraschini F. Immunomodulatory effects of two extracts of Panax ginseng C.A. Meyer. Drugs Exper Clin Res. 1990; 16(10):537-542.
164. Scaglione F, Cattaneo G, Alessandria M, Cogo R. Efficacy and safety of the standardized Ginseng extract G115 of potentiating vaccination against the influenza syndrome and protection against the common cold. Drugs Exper Clin Res. 1996;22(2):65-72.
165. Stevenson H, Tsang KY. Tumor immunology. In: Virella G, ed. Introduction to Medical Immunology. 3rd ed. New York: Marcel Dekker; 1993:497-515.
166. Kopreski MS. Interactions between chemotherapeutic drugs and biologic agents. In: Chabner BA, Long DL, eds. Cancer-Chemotherapy and Biotherapy. 2nd ed. Philadelphia: Lippincott-Raven; 1996:765-785.
167. Xiaoguang C, Hongyan L, Xiaohong L, et al. Cancer chemopreventive and therapeutic activities of red ginseng. J Ethnopharmacol. 1998;60(1):71-78.
168. Lin SY, Liu LM, Wu LC. Effects of Shenmai injection on immune function in cancer patients after chemotherapy. Chung-Kuo Chung Hsi i Chieh Ho Tsa Chih. 1995;15(8):451-453.
169. Zee-Cheng RK. Shi-quan-da-bu-tang (ten significant tonic decoction), SQT. A potent Chinese biological response modifier in cancer immunotherapy, potentiation and detoxification of anticancer drugs. Methods Find Exp Clin Pharmacol. 1992; 14(9):725-736.
170. Shen RN, Lu L, Jia XQ, Wong ML, Kaiser HE. Naturin: a potent bio-immunomodifier in experimental studies and clinical trials. In Vivo. 1996;10(2):201-209.
171. Xie FY, Zeng ZF, Huang HY. Clinical observation on nasopharyngeal carcinoma treated with combined therapy of radiotherapy, and ginseng polysaccharide injection. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2001;21(5):332-334.
172. Suh SO, Kroh M, Kim NR, Joh YG, Cho MY. Effects of red ginseng upon postoperative immunity and survival in patients with Stage III gastric cancer. Am J Chin Med. 2002;30(4):482-494.
173. Wang M, Guilbert JL, Ling L, et al. Immunomodulating activity of CVT-E002, a proprietary extract North American ginseng (Panax quinquefolium). J Pharm PharmacoL 2001;53(11):1515-1523.
174. Vereshchagen IA. Treatment of dysentery in children with combination of monomycin and eleutherococcus. Antibiotiki (Moscow). 1978;23:633.
175. Bohn B, Nebe CT, Birr C. Flow-cytometric studies with eleutherococcus senticosus extract as an immunomodulatory agent. Arzneimittelforschung. 1987;37(10):1193-1196.
176. Chang YS, Seo E, Gyllenhaal C, Block KI. Panax ginseng: a role in cancer therapy? Int Cancer Ther. 2003;2(1):13-33.
177. Beinfeield H, Korngold E. The cauldron of Chinese herbs. In: Between Heaven and Earth. New York: Ballantine; 1991:265-321.
178. Bensky D, Gamble A. Chinese Herbal Medicine: Materia Medica. Rev ed. Seattle, Wash: Eastland Press; 1993.
179. Yu RC, Guan CF, Zhang JH. Immune function of cancer patients with spleen-deficiency syndrome. Chin J Modern Dev Tradit Med. 1990;10(9):535-537, 516.
180. Sun Y, Hersh EM, Lee SL, McLaughlin M, Loo TL, Mavligit GM. Preliminary observations on the effects of the Chinese medicinal herbs Astragalus membranaceus and Ligustrum lucidum on lymphocyte blastogenic responses. J Biol Response Mod. 1983;2(3):227-237.
181. Li XY. Immunomodulating Chinese herbal medicines. Memorias do Instituto Oswaldo Cruz. 1991;86(suppl 2):159-164.
182. Miller AL. Botanical influences on cardiovascular disease. Alt Med Rev. 1998;3(6):422-431.
183. Sun Y, Hong WJ, Deng J. 10-year follow-up study of cancer patients with fu-zheng therapy. Chin J Modern Dev Tradit Med. 1987;7(12):712-714, 707.
184. Zhang XQ, Liu SJ, Pan XY. Clinical study on treatment of chemo- or radiotherapy induced leukopenia with fu-zheng compound. Chung-Kuo Chung Hsi i Chieh Ho Tsa Chih. 1996;16(1):27-28.
185. Hong YH. Oriental Materia Medica: A Concise Guide. Long Beach, Calif: Oriental Healing Arts Institute; 1986.
186. Wang D, Shen W, Tian Y, Sun Z, Jiang C, Yuan S. Protective effect of active components extracted from radix Astragali on human erythrocyte membrane damages caused by reactive oxygen species. China J Chin Mat Med. 1996;21(12):746-748, 763.
187. Yoshida Y, Wang MQ, Liu JN, Shan BE, Yamashita U. Immunomodulating activity of Chinese medicinal herbs and Oldenlandia diffusa in particular. Int J Immunopharmacol. 1997;19(7):359-370.
188. Peng T, Riesemann H, Kandolf R. The inhibitory effect of Astragalus membranaceus on coxsackie B3 virus RNA replication. Chin Med Sci J. 1995;10:146-150.
189. Yuan WL, Chen HZ, Yang YZ, et al. Effect of astragalus membranaceus on electric activities of cultured rat beating heart cells infected with Coxsackie B-2 virus. Chin Med J. 1990;103(3):177-182.
190. Guo Q, Peng TQ, Yang YZ. Effect of Astragalus membranaceus on Ca 2+ influx and coxsackie virus B3 replication in cultured neonatal rat heart cells.
191. Wang RT, Shan BE, Li QX. Extracorporeal experimental study on immuno-modulatory activity of Astragalus memhranaceus extract. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002;22(6):453-456.
192. Wang Y, Qian XJ, Hadley HR, Lau BH. Phytochemicals potentiate interleukin-2 generated lymphokine-activated killer cell cytotoxicity against murine renal cell carcinoma. Mol Biother. 1992;4:143-146.
193. Chu DT, Lin JR, Wong W. The in vitro potentiation of LAK cell cytotoxicity in cancer and AIDS patients induced by F3-a fractionated extract of Astragalus membranaceus. Chung Hua Chung Liu Tsa Chih. 1994;16:167-171.
194. Chu DT, Lepe-Zuniga J, Wong WL, LaPushin R, Mavligit GM. Fractionated extract of Astragalus membranaceus, a Chinese medicinal herb, potentiates LAK cell cytotoxicity generated by a low dose of recombinant interleukin-2. J Clin Lab Immunol. 1988;26(4):183-187.
195. Lau BH, Ruckle HC, Botolazzo T, Lui PD. Chinese medicinal herbs inhibit growth of murine renal cell carcinoma. Cancer Biother: 1994;9(2):153-161.
196. Rittenhouse JR, Lui PD, Lau BH. Chinese medicinal herbs reverse macrophage suppression induced by urological tumors. J Urol. 1991;146(2):486-490.
197. Chu DT, Wong WL, Mavligit GM. Immunotherapy with Chinese medicinal herbs: II. Reversal of cyclophosphamide-induced immune suppression by administration of fractionated Astragalus membranaceus in vivo. J Clin Lab Immunol. 1988;25(3):125-129.
198. Zhao KS, Mancini C, Doria G. Enhancement of the immune response in mice by Astragalus membranaceus extracts. Immunopharmacology. 1990;20(3):225-233.
199. Jin R, Wan LL, Mitsuishi T. Effects of shi-ka-ron and Chinese herbs in mice treated with anti-tumor agent mitomycin C. Chung-Kuo Chung Hsi i Chieh Ho Tsa Chih. 1995;15(2):101-103.
200. Khoo KS, Ang PT. Extract of Astragalus membranaceus and ligustrum lucidum does not prevent cyclophosphamide-induced myelosuppression. Singapore Med J. 1995;36(4):387-390.
201. Zhao KW, Kong HY. Effect of Astragalan on secretion of tumor necrosis factor in human peripheral mononuclear cells. Chung Kuo Hsi I Chieh Ho Tsa Chih. 1993;13:263-265.
202. Sun Y, Hersh EM, Talpaz M, et al. Immune restoration and/or augmentation of local graft versus host reaction by traditional Chinese medicinal herbs. Cancer: 1983;52(1):70-73.
203. Chu DT, Wong WL, Mavligit GM. Immunotherapy with Chinese medicinal herbs: I. Immune restoration of local xenogeneic graft-versus-host reaction in cancer patients by fractionated Astragalus membranaceus in vitro. J Clin Lab Immunol. 1988;25(3):119-123.
204. Hou YD, Ma GL, Wu SH, Li YY, Li HT. Effect of Radix Astragali seu Hedysari on the interferon system. Chin Med J. 1981; 94(1):35-40.
205. Anonymous. Immunity parameters and blood CAMP changes in normal persons after ingestion of radix astragali. Natl Med J China. 1979;59:31-34.
206. Cha RJ, Zeng DW, Chang QS. Non-surgical treatment of small cell lung cancer with chemo-radio-immunotherapy and traditional Chinese medicine. Chung Hua Nei Ko Tsa Chih. 1994;33:462-466.
207. Duan P, Wang ZM. Clinical study on effect of Astragalus in efficacy enhancing and toxicity reducing of chemotherapy in patients of malignant tumor. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002;22(7):515-517.
208. Li NQ. Clinical and experimental study on shen-qi injection with chemotherapy in the treatment of malignant tumor of digestive tract. Zhonggou Zhong Xi Yi Jie Ha Za Zhi. 1992; 12(10):588-592.
209. Huang ZQ Qin NP, Ye W. Effect of Astragalus membranaceus on T-lymphocyte subsets in patients with viral myocarditis. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih. 1995;15:328-330.
210. Yang YZ, Jin PY, Guo Q et al. Effect of Astragalus membranaceus on natural killer cell activity and induction of alpha- and gamma-interferon in patients with coxsackie B viral myocarditis. Chung-Hua I Hsheh Tsa Chih. (English ed) 1990; 103(4):304-307.
211. Zhao XZ. Effects of Astragalus membranaceus and Tripterygium hypoglanucum on natural killer cell activity of peripheral blood mononuclear cells in systemic lupus erythematous. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih. 1992; 12:679-671.
212. Woo WS, Lee EB, Change I. Biological evaluation of Korean medicinal plants: II. Yakhak Hoe Chi. 1977;21:177-183.
213. Lim DY. A study on the hypotensive action of Astragali Radix water extract in the rabbit. Yakhak Hoe Chi. 23:69-80.
214. Li Y, Liu XJ, Zhao LB, Xue SZ. Study on the antidotal effect against intoxication of dimethoate with extract from Astragalus membranaceus in guinea pig. Gongye Weisheng Yu Zhiyebing. 1994; 20:331-334.
215. Yuan WL, Chen HZ, Yang YZ, Yang XY, Lin YS,Jin PY. Effect of Astragalus membranaceus on electric activities of cultured rat beating heart cells infected with Coxsackie B-2 virus. Chung-Hua Hsueh Tsa Chih. (English ed) 1990;103:177-182.
216. Zhou JY, Fan Y, Kong JL, Wu DZ, Hu ZB. Effects of components isolated from Astragalus membranaceus on cardiac function injured by myocardial ischemia reperfusion in rats. Zhonggou Zhongyao Zazhi. 2000;25:300-302.
217. Song MJ, Kim H. Inhibitory effect of herbal medicines on rota-virus infection. Korean J Pharmacognosy. 1998;29:125-128.
218. Beinfeield H, Korngold E. Philosophy in the East: the doctor as gardener. In: Between Heaven and Earth. New York: Ballantine; 1991:29-47.
219. Borchers AT, Hackman RM, Keen CL, Stern JS, Gershwin ME. Complementary medicine: a review of immunomodulatory effects of Chinese herbal medicines. Am J Clin Nutr. 1997; 66(6):1303-1312.
220. Matsuo R, Ball MA, Kobayashi M, Herndon DN, Pollard RB, Suzuki F. Effects of a traditional Chinese herbal medicine, Kanzo-bushi-to, on the resistance of thermally injured mice infected with herpes simplex virus type 1. Int J Immunopharmacol. 1994;16(10):855-863.
221. Liu J, Burdette JE, Xu H, et al. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem. 2001;49(5):2472-2479.
222. Herberman RB. Multiple functions of natural killer cells, including immunoregulation as well as resistance to tumor growth. Concepts Immunopathol. 1985;1:96-132.
223. Vujanovic NL, Basse P, Herberman RB, Whiteside TL. Antitumor functions of natural killer cells and control of metastases. Methods. 1996;9:394-408.
224. Hanna N. Role of natural killer cells in control of cancer metastasis. Cancer Metastasis Rev. 1982;1(1):45-64.
225. Miller JS. The biology of natural killer cells in cancer, infection, and pregnancy. Exp Hematol. 2001;29(10):1157-1168.
226. Rosenberg AS, Brown AE. Infection in the cancer patient. Disease-A-Month. 1993;39(7):505-569.
227. Mandell LA. Infections in the compromised host. J Int Med Res. 1990;18(3):177-190.
228. Takanami I, Takeuchi K, Giga M. The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thoracic Cardiovasc Surg. 2001;121(6):1058-1063.
229. Fujisawa T, Yamaguchi Y. Autologous tumor killing activity as a prognostic factor in primary resected nonsmall cell carcinoma of the lung. Cancer. 1997;79(3):474-481.
230. Yamasaki S, Kan N, Harada T, et al. Relationship between immunological parameters and survival of patients with liver metastases from breast cancer given immuno-chemotherapy. Breast Cancer Res Treat. 1993;26(1):55-65.
231. Carballido J, Alvarez-Mon M, Solovera OJ, Menendez-Ondina L, Durantez A. Clinical significance of natural killer activity in patients with transitional cell carcinoma of the bladder. J Urol. 1990;143(1):29-33.
232. Takeuchi H, Maehara Y, Tokunaga E, Koga T, Kakeji Y, Sugimachi K. Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. Am J Gastroenterol. 2001;96(2):574-578.
233. Berghella AM, Pellegrini P, Del Beato T, Maccarone D, Adorno D, Casciani CU. Prognostic significance of immunological evaluation in colorectal cancer. Cancer Biother Radiopharm 1996;11(6):355-361.
234. Orsi AJ, Tax AW, Nuamah I, Barsevick A, McCorkle R. Natural killer cells over time in patients with colorectal cancer. Cancer Pract. 1996;4(5):252-257.
235. Beitsch P, Lotzova E, Hortobagyi G, Pollock R. Natural immunity in breast cancer patients during neoadjuvant chemotherapy and after surgery. Surg Oncol. 1994;3(4):211-219.
236. Specter SC, Klein TW, Newton C, Mondragon M, Widen R, Friedman H. Marijuana effects on immunity: suppression of human natural killer cell activity of delta-9-tetrahydrocannabinol. Int J Immunopharmacol. 1986;8(7):741-745.
237. Yeager MP, Colacchio TA, Yu CT, et al. Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology. 1995;83(3):500-508.
238. Frank MG, Hendricks SE, Bessette D, Johnson DR, Wieseler Frank JL, Burke WJ. Levels of monocyte reactive oxygen species are associated with reduced natural killer cell activity in major depressive disorder. Neuropsychobiology. 2001;44(1):1-6.
239. Margaretten NC, Hincks JR, Warren RP, Coulombe RA Jr. Effects of phenytoin and carbamazepine on human natural killer cell activity and genotoxicity in vitro. Toxicol Appl Pharmacol. 1987;87(1):10-7.
240. Whalen MM, Loganathan BG, Kannan K. Immunotoxicity of environmentally relevant concentrations of butyltins on human natural killer cells in vitro. Environ Res. 1999;81(2):108-116.
241. Vitaliano PP, Scanlan JM, Ochs HD, Syrjala K, Siegler IC, Snyder EA. Psychosocial stress moderates the relationship of cancer history with natural killer cell activity. Ann Behav Med. 1998;20(3):199-208.
242. Levy S, Herberman R, Lippman M, d'Angelo T. Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer. J Clin Oncol. 1987;5 (3):348-353.
243. Levy SM, Herberman RB, Lippman M, D'Angelo T, Lee J. Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer. Behav Med. 1991;17(2):67-75.